Atara Biotherapeutics Inc
NASDAQ:ATRA
Intrinsic Value
The intrinsic value of one
ATRA
stock under the Base Case scenario is
9.51
USD.
Compared to the current market price of 2.87 USD,
Atara Biotherapeutics Inc
is
Undervalued by 70%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
ATRA Profitability Score
Profitability Due Diligence
Atara Biotherapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Atara Biotherapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
ATRA Solvency Score
Solvency Due Diligence
Atara Biotherapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Atara Biotherapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Atara Biotherapeutics Inc
| Current Assets | 295M |
| Cash & Short-Term Investments | 243M |
| Receivables | 40.2M |
| Other Current Assets | 12M |
| Non-Current Assets | 81.3M |
| PP&E | 74.3M |
| Other Non-Current Assets | 7M |
| Current Liabilities | 78.9M |
| Accounts Payable | 6.9M |
| Accrued Liabilities | 63.2M |
| Other Current Liabilities | 8.8M |
| Non-Current Liabilities | 171M |
| Long-Term Debt | 3.6M |
| Other Non-Current Liabilities | 167M |
ATRA Capital Structure
Atara Biotherapeutics Inc
| Market Capitalization | 275M USD | |
| Total Debt | 3.6M USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 92.9M USD | |
| Short-Term Investments | 150M USD | |
| Enterprise Value | 36.1M USD | |
Wall St
Price Targets
ATRA Price Targets Summary
Atara Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ATRA
is 18.87 USD
with a low forecast of 2.02 USD and a high forecast of 52.5 USD.
Ownership
ATRA Insider Trading
Buy and sell transactions by insiders
During the last 12 months Atara Biotherapeutics Inc insiders have not bought any shares, and sold 682k USD worth of shares. The last transaction was made on Mar 25, 2023 by Touchon Pascal (President and CEO), who sold 56.9k USD worth of ATRA shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
129k
USD
|
N/A
|
-129.1k
|
| 6 Months |
263k
USD
|
N/A
|
-262.9k
|
| 9 Months |
508k
USD
|
N/A
|
-507.7k
|
| 12 Months |
682k
USD
|
N/A
|
-682.1k
|
Shareholder Return
ATRA Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
ATRA Price
Atara Biotherapeutics Inc
| Average Annual Return | -15.52% |
| Standard Deviation of Annual Returns | 29.9% |
| Max Drawdown | -94% |
| Market Capitalization | 275M USD |
| Shares Outstanding | 101 990 000 |
| Percentage of Shares Shorted | 13.03% |
Company Profile
Atara Biotherapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
Contact
IPO
Employees
Officers
The intrinsic value of one
ATRA
stock under the Base Case scenario is
9.51
USD.
Compared to the current market price of 2.87 USD,
Atara Biotherapeutics Inc
is
Undervalued by 70%.
